Aurobindo Pharma Gets USFDA Approval For Duloxetine Hydrochloride Capsules
(RTTNews) - The Hyderabad-based Aurobindo Pharma Ltd. announced that the company had received tentative approval from the US FDA to manufacture and market Duloxetine Hydrochloride Delayed-Release capsules 20mg (base), 30mg (base) and 60mg (base).
Duloxetine Hydrochloride Delay-Release capsules are the generic equivalent of Eli Lilly and Company's Cymbalta Delayed-Release capsules 20mg (base), 30mg (base) and 60mg (base).
Duloxetine Hydrochloride Delayed-Release capsules are indicated for the treatment of major depressive disorder and fall under the Neurological therapeutic category.
As per IMS data, the product has a market size of around $2.9 billion for the twelve months ended June 2010.
At the BSE, Aurobindo Pharma shares are being traded at Rs.1,301, up by 0.143% from the previous close.
December 08, 2010